In a mouse model of this disease, the granulomatous inflammation (which was considered as a nearly mesothelioma like symptom) was greatly attenuated in SphK1−/− mice as compared to SphK1+/+ mice (41) indicating the possibility of targeting SphK1 for the treatment of mesothelioma. This evidence concerns the gene SPHK1 and inflammatory response.